Ritlecitinib effectively reduces psychosocial burden in severe alopecia areata, beyond hair regrowth benefits. Significant improvements in emotional symptoms and activity limitations were observed ...

More than half of adolescents treated with baricitinib achieved complete or near-complete scalp hair regrowth at 1 year, with those who initiated treatment before completely losing their hair being ...

Baricitinib (Olumiant; Eli Lilly), an oral Janus kinase (JAK) 1/2 inhibitor, led to significant scalp, eyelash, and eyebrow hair regrowth at 52 weeks in adolescents with severe alopecia areata, ...

Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.’ This study aims to assess the safety and efficacy of ritlecitinib, a potential treatment for ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

This trial is the first and largest study specifically designed to evaluate children and adolescents with severe alopecia areata, a population often underrepresented in clinical trials New data show ...

Explore the latest advances in alopecia areata treatment, including FDA-approved JAK inhibitors and promising topical solutions, offering new hope for hair regrowth.

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...